ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314

Its studies are mostly in Colorectal Neoplasms, led by BioNTech.

Furthest: phase 2, since Jul 9, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech22 open or runningphase 2since Jul 9, 2025Nov 21, 2023Dec 2030phase 2 · NCT07079631

Also a collaborator on its studies: Genmab.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 21, 2023First study: phase 1 study in Advanced Malignant Solid TumorFirst studyNCT06150183 · 41 enrolled · United States, Belgium, Denmark and more
  2. Jul 9, 2025Phase 2 study in Colorectal NeoplasmsNCT07079631 · 482 planned · United States, Germany, Japan and more

Ahead

  1. Dec 2030Primary completion: phase 2 study in Colorectal NeoplasmsNCT07079631

TargetBeta

“An Fc-inert bispecific antibody directed against the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07079631Colorectal Neoplasms · United States, Germany, Japan and more2RecruitingDec 2030482
NCT06150183Advanced Malignant Solid Tumor · United States, Belgium, Denmark and more1Active, not recruitingAug 18, 202641

How it is read

Names in the registry

  • “BNT314”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.